Amneal 8-K/A Reveals Kashiv Going-Concern Doubt and Restatement in Deal Financials
AMRX has more than doubled off its 52-week low of $9.99 on elevated volume (1.8× avg).
Summary
Amneal's 8-K/A files Kashiv's audited and interim financials plus pro forma results for the August 10, 2026 acquisition, disclosing a going-concern doubt at Kashiv, a 2024 restatement, and a pro forma swing to a $78.2 million 2025 loss attributable to Amneal.
Key Events · M&A and Partnerships · AMRX
-
Kashiv Financials Filed With Going-Concern Doubt
Grant Thornton's audit report on Kashiv states substantial doubt about its ability to continue as a going concern, citing approximately $106.3 million of cash used in operations in 2025 and a $27.7 million accumulated deficit at December 31, 2025.
-
Kashiv Restated 2024 Financials
Kashiv's 2024 consolidated statements were restated to correct misstatements in the Pipan and Kashiv India acquisition accounting and an unrecorded lease modification, cutting 2024 members' deficit by $7.7 million.
-
Pro Forma Swings Amneal to 2025 Loss
Giving effect to the deal as of January 1, 2025, net income attributable to Amneal falls from $72.1 million historical to a pro forma loss of $78.2 million; for six months of 2026 it drops from $119.9 million to $17.2 million.
-
$1.31B Preliminary Consideration Allocated
Preliminary aggregate consideration is $1,305.6 million, including $491.6 million of equity (28,942,108 shares at $17.88 with a 5% marketability discount) and $389.0 million fair value of contingent milestone and royalty payments; the allocation books $963.1 million of indefinite-lived IPR&D and $169.9 million of goodwill.
Analysis · AMRX · Life Sciences
The financial statements Amneal owed investors after closing the Kashiv acquisition on August 10, 2026 are now on file, and they are worse than the headline deal suggested. Grant Thornton's audit of Kashiv carries an explicit substantial-doubt going-concern paragraph: Kashiv burned about $106.3 million of operating cash in 2025 and ended the year with a $27.7 million accumulated deficit. Kashiv also restated its 2024 statements to fix misstatements tied to the Pipan and Kashiv India acquisitions and a lease modification. What Amneal is absorbing shows up in the pro forma tables: on a combined basis, 2025 swings from $72.1 million of net income attributable to Amneal to a $78.2 million loss, and six-month 2026 net income drops from $119.9 million to $17.2 million. Amneal is paying $1,305.6 million in preliminary aggregate consideration, including 28,942,108 shares and $389.0 million of contingent consideration, and books $963.1 million of indefinite-lived IPR&D that will not be amortized until the programs resolve. The acquired losses are now Amneal's problem to fund.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 36.8% of the 1025 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMRX was trading at $20.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.5B. The 52-week trading range was $9.99 to $21.18. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.